CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)
$3.42 0.1 (3.012%)
Analysed CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) News Sources
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments
11-06-2026
yahoo.com
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
19-06-2026
yahoo.com
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
08-07-2026
yahoo.com
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
27-07-2026
yahoo.com
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
30-07-2026
yahoo.com
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
03-08-2026
yahoo.com
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
06-08-2026
yahoo.com
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
06-08-2026
yahoo.com
CytomX Therapeutics Q2 Earnings Call Highlights
07-08-2026
marketbeat.com
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
07-08-2026
yahoo.com
What is the current price of CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)?
The current price of CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) is $3.42.
CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) absolute price change since previous trading day?
The absolute price change of CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) since the previous trading day is $0.1.
CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) percentage price change since previous trading day?
The percentage price change of CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) since the previous trading day is 3.012%.
What is the most recent average sentiment score for CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)?
The most recent average sentiment score for CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)?
The most recent sentiment for CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) is .
SEC-8K** Filing Available For CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.